Skip to main content

Research Repository

Advanced Search

All Outputs (3)

Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia (2021)
Thesis
Naylor-Adamson, L. (2021). Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4224129

Ibrutinib is highly effective in the treatment of chronic lymphocytic leukaemia (CLL), disrupting B cell receptor signalling through the inhibition of Bruton’s tyrosine kinase (Btk). However, ibrutinib has off-target effects, inhibiting platelet aggr... Read More about Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia.

The role of the Kinin-Kallikrein System in chronic lymphocytic leukaemia (2014)
Thesis
Kashuba, E. (2014). The role of the Kinin-Kallikrein System in chronic lymphocytic leukaemia. (Thesis). Hull York Medical School, the University of Hull and the University of York. Retrieved from https://hull-repository.worktribe.com/output/4216406

Background: Chronic lymphocytic leukaemia (CLL) is an incurable heterogeneous disease. The identification of reliable and cost effective biomarkers is therefore imperative. A comparative proteomic approach was previously employed to study protein ex... Read More about The role of the Kinin-Kallikrein System in chronic lymphocytic leukaemia.

The proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia (2009)
Thesis
Eagle, G. L. (2009). The proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia. (Thesis). University of Hull. Retrieved from https://hull-repository.worktribe.com/output/4209165

Chronic Lymphocytic Leukaemia (CLL) is the most common adult Leukaemia in the UK, Western Europe and America. It is a malignancy of naive B-cells. The clinical course of patients with CLL is heterogeneous; some patients survive for years without trea... Read More about The proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia.